United States · Platforms & data · MarketBeat

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Published by MarketBeat · United States 2 h ago

Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

2 Quantum Computing Stocks That Could Help Make You a Fortune

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

MarketWatch

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

TheStreet

Vanguard flags a hidden AI risk in your value fund

Stocktwits

AI Tokens Post A Mixed Bag As Grayscale Spotlights Three Projects Beyond TAO, NEAR And WLD

Morningstar